These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 8097624)
1. Saturable enantioselective first-pass effect for carvedilol after high oral racemate doses in rats. Stahl E; Henke D; Mutschler E; Spahn-Langguth H Arch Pharm (Weinheim); 1993 Mar; 326(3):123-5. PubMed ID: 8097624 [TBL] [Abstract][Full Text] [Related]
2. Carvedilol stereopharmacokinetics in rats: affinities to blood constituents and tissues. Stahl E; Mutschler E; Baumgartner U; Spahn-Langguth H Arch Pharm (Weinheim); 1993 Sep; 326(9):529-33. PubMed ID: 7902078 [TBL] [Abstract][Full Text] [Related]
3. Rats with portacaval shunt as a potential experimental pharmacokinetic model for liver cirrhosis: application to carvedilol stereopharmacokinetics. Stahl E; Baumgartner U; Henke D; Schölmerich J; Mutschler E; Spahn-Langguth H Chirality; 1993; 5(1):1-7. PubMed ID: 8095396 [TBL] [Abstract][Full Text] [Related]
4. Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound. Neugebauer G; Akpan W; Kaufmann B; Reiff K Eur J Clin Pharmacol; 1990; 38 Suppl 2():S108-11. PubMed ID: 1974498 [TBL] [Abstract][Full Text] [Related]
5. Disposition of carvedilol enantiomers in patients with liver cirrhosis: evidence for disappearance of stereoselective first-pass extraction. Neugebauer G; Gabor M; Reiff K J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S142-6. PubMed ID: 1378143 [TBL] [Abstract][Full Text] [Related]
6. Measurement of carvedilol enantiomers in human plasma and urine using S-naproxen chloride for chiral derivatization. Spahn H; Henke W; Langguth P; Schloos J; Mutschler E Arch Pharm (Weinheim); 1990 Aug; 323(8):465-9. PubMed ID: 1980583 [TBL] [Abstract][Full Text] [Related]
7. Assay and disposition of carvedilol enantiomers in humans and monkeys: evidence of stereoselective presystemic metabolism. Fujimaki M; Murakoshi Y; Hakusui H J Pharm Sci; 1990 Jul; 79(7):568-72. PubMed ID: 1975840 [TBL] [Abstract][Full Text] [Related]
8. Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism. Nardotto GHB; Coelho EB; Paiva CE; Lanchote VL J Clin Pharmacol; 2017 Jun; 57(6):760-769. PubMed ID: 28114735 [TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of R- and S-carvedilol in Japanese patients with chronic heart failure. Saito M; Kawana J; Ohno T; Hanada K; Kaneko M; Mihara K; Shiomi M; Nagayama M; Sumiyoshi T; Ogata H Biol Pharm Bull; 2010; 33(8):1378-84. PubMed ID: 20686235 [TBL] [Abstract][Full Text] [Related]
10. Effects of cilostazol on the pharmacokinetics of carvedilol after oral and intravenous administration in rats. Lim TH; Cho YA; Choi DH J Physiol Pharmacol; 2015 Aug; 66(4):591-7. PubMed ID: 26348083 [TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients. Nardotto GHB; Lanchote VL; Coelho EB; Della Pasqua O Eur J Pharm Sci; 2017 Nov; 109S():S108-S115. PubMed ID: 28522373 [TBL] [Abstract][Full Text] [Related]
12. Dose-effect and pharmacokinetic-pharmacodynamic relationships of the beta 1-adrenergic receptor blocking properties of various doses of carvedilol in healthy humans. de Mey C; Breithaupt K; Schloos J; Neugebauer G; Palm D; Belz GG Clin Pharmacol Ther; 1994 Mar; 55(3):329-37. PubMed ID: 7908256 [TBL] [Abstract][Full Text] [Related]
13. Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats. Kim MS; Baek IH Eur J Pharm Sci; 2018 Jan; 111():13-19. PubMed ID: 28942006 [TBL] [Abstract][Full Text] [Related]
15. Stereoselective oxidation and glucuronidation of carvedilol in human liver and intestinal microsomes. Ishida K; Taira S; Morishita H; Kayano Y; Taguchi M; Hashimoto Y Biol Pharm Bull; 2008 Jun; 31(6):1297-300. PubMed ID: 18520073 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of R- and S-carvedilol in routinely treated Japanese patients with heart failure. Horiuchi I; Nozawa T; Fujii N; Inoue H; Honda M; Shimizu T; Taguchi M; Hashimoto Y Biol Pharm Bull; 2008 May; 31(5):976-80. PubMed ID: 18451529 [TBL] [Abstract][Full Text] [Related]
17. Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs. Beddies G; Fox PR; Papich MD; Kanikanti VR; Krebber R; Keene BW Am J Vet Res; 2008 Dec; 69(12):1659-63. PubMed ID: 19046015 [TBL] [Abstract][Full Text] [Related]
18. Exercise does not affect plasma concentrations of (R)- and (S)-carvedilol. Stoschitzky K; Koshucharova G; Zweiker R; Lercher P; Maier R; Klein W; Zitta S; Gruber L; Lamprecht G; Lindner W Cardiovasc Drugs Ther; 2002 Mar; 16(2):133-40. PubMed ID: 12090906 [TBL] [Abstract][Full Text] [Related]
19. Chiral analysis of carvedilol and its metabolites hydroxyphenyl carvedilol and O-desmethyl carvedilol in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical pharmacokinetic study. Nardotto GHB; Coelho EB; Marques MP; Lanchote VL J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Mar; 1015-1016():173-180. PubMed ID: 26927877 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and disposition of carvedilol in humans. Neugebauer G; Akpan W; von Möllendorff E; Neubert P; Reiff K J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S85-8. PubMed ID: 2454375 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]